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Abstract Hypertension is a risk factor for renal impair-
ment. While treatment of hypertension provides significant
renal protection, there is still an unmet need requiring
further exploration of additional pathogenetic mechanisms.
We have found that the hypertension-related, calcium-
regulated gene (HCaRG/COMMD5) is involved in renal
repair. HCaRG is a small intracellular protein of 225 amino
acids and its gene expression is negatively regulated by
extracellular calcium concentrations. HCaRG is mostly
expressed in the kidneys, with higher levels found in the
spontaneously hypertensive rat than in normotensive rats.
In an acute kidney injury model, HCaRG expression
decreases immediately after injury but increases above
baseline during the repair phase. In cell cultures, HCaRG
has been shown to facilitate differentiation and to inhibit
cell proliferation via p21 transactivation through the p53-
independent signaling pathway. Induction of p21 inde-
pendently of p53 is also observed in transgenic mice
overexpressing HCaRG during the repair phase after
ischemia/reperfusion injury, resulting in their improved
renal function and survival with rapid re-differentiation of
proximal tubular epithelial cells. In addition, transgenic
mice recover rapidly from the inflammatory burst most
likely as a result of maintenance of the tubular epithelial
barrier. Recent studies indicate that facilitating re-differ-
entiation and cell cycle regulation in injured renal proximal
tubules might be important functions of HCaRG. We have
proposed that HCaRG is a component of differential
genetic susceptibility to renal impairment in response to
hypertension.
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Introduction
High blood pressure is a risk factor for renal failure. It is
well known that malignant hypertension leads to kidney
injury and that mild to moderate chronic hypertension
can accelerate the progression of renal disease. Para-
doxically, the most used animal model of human hyper-
tension, the spontaneously hypertensive rat (SHR), is
relatively resistant to renal damage not only when com-
pared to other hypertensive rat models, such as the Dahl
salt-sensitive rat or the Munich hypertensive strain, but
also in comparison to normotensive rats such as the
Brown–Norway (BN) rat, suggesting that genetic factors
may affect the susceptibility to hypertension-induced or
-accelerated renal disease. This has been well demon-
strated by elegant studies of Theodore W. Kurtz’s group
when they transplanted a kidney of the BN rat to the
uninephrectomized SHR: it resulted in more severe kid-
ney damage to the BN donor kidney than to the SHR
kidney [1]. Our review focuses here on a hypertension-
related gene, hypertension-related, calcium-regulated gene
(HCaRG/COMMD5) that is more expressed in kidneys of
SHR than of normotensive rats, and could explain in part
the resistance of the SHR kidney by its accelerating
effects on renal repair.
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Discovery of HCaRG
HCaRG was initially discovered by our group in the
parathyroid glands of the SHR and shown to be negatively
regulated by extracellular calcium concentrations. It
encodes a small intracellular protein of 225 amino-acids
[2]. Incubation of parathyroid cells under the low extra-
cellular calcium condition increases HCaRG expression in
the same manner as parathyroid hormone. Other hormones,
such as natriuretic peptides and vasopressin, have also been
shown to respond to low extracellular calcium concentra-
tions, but HCaRG is the first intracellular protein reported
to have this property, and all these genes, including
HCaRG, possess a negative calcium-responsive element in
their promoters [3].
Hypertension is one of the risk factors not only for
kidney injuries but also for renal cell carcinoma (RCC) [4–
7]. Genetic hypertension is characterized at birth by sup-
pression of apoptosis and increment of cell proliferation,
leading to neonatal heart and kidney hyperplasia [8].
During the period of hypertension development, apoptosis
is increased in response to the increment of blood pressure
but so is proliferation, resulting in acceleration of cell
turnover. The HCaRG gene exists in one copy on human
chromosome 8q24.3 with paralogs on syntenic regions of
rat chromosome 7 and mouse chromosome 15. This locus
is associated with kidney weight (KW), urinary calcium
excretion in rats and oncogenesis in humans [9, 10].
Chromosome 8 abnormalities, which might be of particular
pathogenic importance, can be detected in 15 % of patients
with acute myeloid leukemia [11, 12]. Gains and high-level
gene amplification at 8q have been reported in renal cell
carcinoma (RCC), metastatic prostate cancers, sporadic
colorectal carcinomas and metastatic gastrointestinal stro-
mal tumors [13–18]. Chromosome 8 anomalies in certain
cancers could disrupt the HCaRG gene. In fact, HCaRG
levels are decreased in various cancer cell lines [2].
HCaRG levels are more abundant in the kidneys, heart and
adrenal glands. HCaRG is mainly located in renal proximal
tubules (RPTs) of kidneys. We became interested in the
possible roles played by HCaRG in the process of kidney
development and renal repair after injury.
HCaRG as a member of the COMMD protein family
HCaRG has been assigned to a novel copper metabolism
MURR1 domain-containing (COMMD) protein family,
based on the identification of a well-conserved and unique
domain at its carboxy-terminal end the COMM domain.
The COMMD protein family has 10 members, and HCaRG
corresponds to COMMD5. The length of the COMM
domain varies between 70 to 85 amino acids across
members of the family. The prototype of the COMMD
protein family, COMMD1, exerts the function of blocking
nuclear factor of kappa light polypeptide gene enhancer in
B-cells (NF-jB)-chromatin interaction which, in turn, is
induced by various stimuli, including tumor necrosis factor
(TNF) and interleukin (IL)-1b [19, 20]. It has been deter-
mined that all members of the COMMD family are capable
of inhibiting NF-jB transcriptional activity to various
degrees and that the COMM domain is critical in the
process. Recently, we reported that transgenic (Tg) mice
overexpressing HCaRG/COMMD5 in RPTs recovered
rapidly from the inflammatory burst that increased TNF-a
and IL-1b as well as infiltration of macrophages after acute
kidney injury (AKI) [21].
The COMM domain, which defines all COMMD pro-
teins and is well conserved among members of this protein
family, provides a critical interface for protein–protein
interactions. It has been established that COMMD proteins
are highly interactive and that the COMM domain mediates
COMMD1-COMMD1 homodimerization as well as bind-
ing to other COMMD proteins [22]. While the COMM
domains of COMMD1 and HCaRG are highly conserved,
87 % of amino acids differ between HCaRG and COM-
MD1 outside this domain, suggesting that members of the
COMMD protein family could have different functions
(Fig. 1).
HCaRG as cell cycle regulator
Renal proximal tubules repair after injury requires de-dif-
ferentiation, proliferation and migration of surviving
tubular cells to replace dead cells [23, 24]. The process of
tubular repair is similar to renal development in the fetal
stage and includes a high cell proliferation rate, soaring
apoptosis and a specific gene expression pattern. Interest-
ingly, Joseph V. Bonventre’s group has demonstrated that
epithelial cell cycle arrest at G2/M during the injury phase
results in the activation of c-jun NH2-terminal kinase sig-
naling, which acts to up-regulate the production of fibro-
genic cytokines, thus accelerating progression of chronic
kidney disease (CKD) [25]. In contrast, inhibition of cell
proliferation with cycle arrest at G1 mediated by rosiglit-
azone, which has been used to decrease insulin resistance
by activating peroxisomal proliferator-activated receptor,
facilitates the recovery of proximal tubular epithelial cells
(PTECs) after cisplatin-induced injury through the down-
regulation of extracellular signal-regulated kinase and Akt
signaling [26].
The effect of HCaRG on cell proliferation was demon-
strated in two kidney cell lines, human embryonic kidney
(HEK)-293 cells and Madin–Darby canine kidney
(MDCK)-C7 cells [27]. The cells were stably transfected
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with either control plasmid (Neo) or HCaRG expression
plasmid (HCaRG). HCaRG-overexpressing cells presented
a much lower proliferation rate (Fig. 2a) and DNA syn-
thesis than control cells. In addition, HCaRG delayed the
cell cycle with accumulation of cells at G2/M, without
arrest [28].
The gene expression profiles of 111 cell cycle regulatory
genes in stably-transfected cells have been analyzed [28].
HCaRG overexpression markedly induced p21 and down-
regulated p27 in HEK-293 cells. HCaRG overexpression
also augmented p21 expression independently of p53
expression in MDCK-C7 cells (Fig. 2b) [21]. This up-
regulation was diminished by HCaRG knockdown with
short-hairpin RNA (shRNA). p21, accompanied by p53 up-
regulation, has been demonstrated to be induced in cells
undergoing either p53-dependent G1 growth arrest or
apoptosis [29]. p21 levels can also rise rapidly by differ-
entiation inducers through a p53-independent pathway. In
that case, p21 induction is coupled with the expression of
early differentiation markers [30]. p21, independently of
p53, could act as an inducible growth inhibitor that con-
tributes to slow down the cell cycle and facilitates differ-
entiation [31].
HCaRG fosters cellular maturation
HCaRG has been associated with changes in cell mor-
phology and the appearance of differentiated phenotypes,
namely, HCaRG-overexpressing HEK-293 cells present
features of mature epithelial cells, such as higher protein
content, cell size and volume [28]. Transmission electron
microscopy ultrastructural analysis has revealed the pre-
sence of more differentiated junctions (desmosome-like) in
HCaRG-overexpressing cells than in Neo controls, and
these cells demonstrate features consistent with junctional
(glandular-like) complex formation and numerous micro-
villi (Fig. 2c). These cellular changes are concordant with
several modifications in the levels of specific epithelial/
mesenchymal markers. E-cadherin, a marker of epithelial
integrity [32], is higher in HCaRG-overexpressing cells
than in control cells (Fig. 2b) [21]. In contrast, vimentin, an
intermediate filament protein that is only expressed in
mesenchymal cells [33], is lower in HCaRG-overexpress-
ing cells. These observations indicate that HCaRG could
accelerate differentiation and maturation via p21 transac-
tivation through a p53-independent pathway in kidney
cells, resulting in delay of the cell cycle with G2/M
accumulation.
HCaRG stimulates renal cell migration
Acute kidney injury evokes actin cytoskeleton disruption
and aggregation by induction of cofilin and, consequently,
causes the breakdown of PTEC apical membrane microvilli
during the early stage after ischemia [34]. Aquaporin-1,
which is widely expressed in epithelial and endothelial cell
membranes and facilitates transepithelial water transport,
accelerates the migration of PTECs by actin re-organiza-
tion, resulting in decreased tubular injury after ischemia
[35]. Such cytoskeletal organization and migration of
PTECs are key events occurring during tubular injury and
repair.
As described previously, HCaRG accelerates differen-
tiation and maturation via p21 transactivation. On the other
hand, HCaRG overexpression increases the motility of
kidney cells through the secretion of transforming growth
factor-a in the wound-healing assay (Fig. 3a) [36]. We
recently examined the intracellular location of HCaRG and
actin in migrating MDCK-C7 cells during wound healing
(Fig. 3b). In non-migrating cells, we observed HCaRG
localization in the perinuclear space and clearly visible
actin fibers with no signs of interactions between the two
proteins. In migrating cells, intracellular actin fibers dis-
appeared, and short filamentous (F)-actin accumulation
was seen between the nucleus and elongated tip. HCaRG
was also seen concentrated with short F-actin between the
Fig. 1 Alignment of human HCaRG/COMMD5 and COMMD1
proteins, excluding the COMM domain. While COMM domains of
the COMMD protein family are highly conserved, HCaRG has only
13 % homology with COMMD1. Asterisks indicate positions with a
single, fully-conserved residue. Colons depict strongly similar
properties—scoring [0.5 in the Gonnet PAM 250 matrix. Periods
indicate weak similarity—scoring B0.5 in the Gonnet PAM 250
matrix. HCaRG hypertension-related calcium-regulated gene, COMM
copper metabolism MURR1
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nucleus and elongated tip. It is known that in migrating
fibroblasts, centrosomes reorient between the nucleus and
elongated tip, which in turn re-positions the Golgi appa-
ratus that is thought to establish and maintain cell polarity
during migration [37–40]. We postulate that HCaRG could
play a role in stimulating cell migration and wound healing
without de-differentiation, by directly involving actin re-
organization.
HCaRG accelerates renal tubular repair after injury
Acute kidney injury
Ischemia/reperfusion injury (IRI) causes acute tubular
damage, one of the most common forms of human AKI.
After renal ischemia with renal hypoperfusion and hypoxia,
PTECs lose their structural integrity through a sequence of
events that include the disruption of brush border with
blebbing of the apical membrane, fragmentation and
internalization, and a rapid change in cell polarity. During
the recovery phase, surviving PTECs proliferate and
replace the irreversibly injured PTECs, migrate to cover
the exposed areas of the basement membrane and re-dif-
ferentiate to restore tubular integrity [23]. In a rat IRI
model, we determined that HCaRG mRNA levels
decreased soon after reperfusion and reached their lowest
levels after 3–6 h, when PTECs were de-differentiated and
proliferated. HCaRG mRNA levels then rose steadily to
higher than baseline 48 h after reperfusion, corresponding
to the regeneration phase [2].
Tg mice overexpressing HCaRG in RPTs were gener-
ated to test the hypothesis that HCaRG could stimulate
renal repair [21]. Exogenous HCaRG was inserted into the
kidney androgen-regulated protein (KAP) promoter plas-
mid. KAP was identified as an abundant protein under
androgen control and expressed in RPTs [41, 42];
bFig. 2 HCaRG controls cell proliferation and facilitates cellular
differentiation. a Cell proliferation in Neo- or HCaRG-plasmid-
transfected HEK-293 and MDCK-C7 cells. HCaRG inhibited cell
proliferation in both kidney cell lines *p \ 0.05, p \ 0.01. b Protein
expression of HCaRG, p53, p21 and differentiation phenotype
markers (E-cadherin and vimentin) in Neo- and HCaRG-plasmid-
transfected MDCK-C7 cells with or without shRNA. HCaRG was
detected only in HCaRG-MDCK cells. HCaRG-MDCK cells showed
more mature gene expression patterns than Neo-MDCK cells. HCaRG
induced p21 transactivation without p53 induction. shRNA-HCaRG
treatment lowered HCaRG levels compared to a non-target control.
HCaRG reduction led to lower p21 expression and abolition of
differentiation in HCaRG-MDCK cells. Data from Matsuda et al.
[21]. c Electron microscopy of Neo- and HCaRG-plasmid-transfected
HEK-293 cells. HCaRG-HEK-293 cells had mature desmosome-like
junctions instead of the tight junctions of Neo-control cells. Scale
bars 300 nm. Figure from Devlin et al. [28]
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Fig. 3 HCaRG stimulates renal
cell migration. a Wound healing
assay in Neo- or HCaRG-
plasmid-transfected HEK-293
cells. HCaRG markedly
accelerated wound healing after
20 h compared to Neo-controls.
Scale bars 50 lm.
b Intracellular location of
F-actin (green) and HCaRG
(red) in migrating MDCK cells
during the wound-healing
process. In non-migrating cells,
HCaRG is located in the
perinuclear space, and
organized actin fibers are clearly
visible. In the migrating cell,
intracellular actin fibers are de-
polymerized and short F-actin
filaments are observed in the
perinuclear space. HCaRG
localizes with short F-actin
filaments between the nucleus
and elongated tip. Nuclei are
stained by DAPI (blue). Scale
bars 25 lm (color figure online)
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therefore, exogenous HCaRG was expressed in RPTs of Tg
male mice under androgen control.
In an AKI model, IRI caused severe tubular damage that
resulted in pronounced renal dysfunction in both non-Tg
and Tg mice [21]. The survival rate 7 days after IRI injury
was 64 % in Tg compared to only 25 % in non-Tg mice
(p = 0.0249). In addition, morphological tubular damage
and renal function in Tg mice improved significantly faster
in comparison to non-Tg mice after 2 days (Table 1). We
concluded that HCaRG overexpression significantly
enhances renal function and survival after ischemia.
Tubular epithelial cells and cells within the interstitial
space, which are associated with vascular network com-
ponents and resident fibroblasts, account for about 80 % of
kidney volume, and increased KW could be due to edema,
hypertrophy and cell proliferation after tubular injury [43].
HCaRG overexpression did not affect renal hypertrophy by
uninephrectomy, but significantly reduced the increase of
KW 2 days after reperfusion (Fig. 4a). Such KW reduction
could have resulted from stimulation of cell death or
inhibition of cell growth. However, we demonstrated that
HCaRG had no effect on apoptotic cell death after IRI. A
large number of proliferating cell nuclear antigen (PCNA)-
positive cells were present in tubules on day 2 (Fig. 4b).
HCaRG overexpression decreased only the number of
proliferating tubular cells, while the number of proliferat-
ing cells in the interstitium was comparable between non-
Tg and Tg mice. This inhibition of PTEC proliferation was
accompanied by p53-independent p21 transactivation. It is
known that p21 transactivation by a p53-independent
pathway occurs in RPTs but not in the glomerulus or
interstitium during the renal recovery phase, and might thus
have contributed to cell differentiation [44–46]. In p21
knockout mice, AKI causes more rapid onset of renal
dysfunction, and induces more severe morphological
damage with a threefold higher mortality rate than in
normal mice [45, 47]. Miyaji et al. [46] reported that cis-
platin-induced AKI evoked 2 peaks of increased p21. The
first peak was accompanied by up-regulation of p53 and
PCNA, possibly reflecting G1 arrest and DNA repair. The
second p21 peak occurred through a p53-independent
pathway likely contributing to cell differentiation. These
studies indicate that p53-independent p21 up-regulation
could be crucial in controlling epithelial proliferation and
morphogenesis in RPTs. Actually, in HCaRG Tg mice,
E-cadherin levels recovered more rapidly, while vimentin
induction after IRI disappeared faster than in non-Tg mice.
Chronic kidney disease
Tubulointerstitial fibrosis is recognized to be a common
endpoint of human CKD caused by hypertension, diabetes,
and nephrotic syndrome. Unilateral ureteral obstruction
(UUO) is used as an animal model of progressive tubulo-
interstitial fibrosis. UUO also leads to many pathophysio-
logical events of obstructive nephropathy, such as cellular
infiltration and proliferation, tubular de-differentiation,
apoptosis and atrophy, fibroblasts differentiation and
excessive extracellular matrix deposition [43, 48].
KW is increased 3 days after obstruction because UUO
produces tubular dilatation and interstitial edema (Fig. 4a)
[21]. HCaRG overexpression does not reduce the initial
edema in Tg mice. Contralateral KW gain until 7 days after
obstruction is mainly due to hypertrophy, and HCaRG
overexpression does not affect this hypertrophy, as in the
uninephrectomized kidneys. Ten days after surgery, UUO
results in gradual KW reduction, and HCaRG overexpres-
sion causes more rapid KW diminution in Tg mice com-
pared to non-Tg mice. This KW reduction also derives
from the imbalance of cell growth and loss. In the
obstructed kidneys after 10 days of UUO, HCaRG over-
expression decreases only the number of proliferating
tubular cells, as after IRI (Fig. 4b).
The results in both IRI and UUO models can be
summarized as follows: (1) HCaRG overexpression does
not reduce initial edema, hypertrophy and injury; (2)
HCaRG overexpression leads to faster KW diminution in
Tg than in non-Tg mice; (3) these KW decreases are due
to inhibition of cell proliferation increment in tubules but
not in the interstitium; (4) HCaRG elicits re-differentia-
tion via p21 induction after injury. In conclusion, HCaRG
does not reduce initial tubular injury, but accelerates
repair of RPTs which improves survival by facilitating re-
differentiation of resident PTECs and controlling prolif-
eration via p21 induction through its p53-independent
pathway.
Finally, slow-cycling renal progenitor-like cells provide
regenerating cells that replace injured cells during the
repair phase after AKI [49, 50]. At an early phase of
tubular regeneration, their daughter cells after multiple cell
division show mesenchymal phenotypes such as active
proliferation and migration in the interstitium, and even-
tually differentiate into PTECs. HCaRG could play a role
in the differentiation and survival of resident renal pro-
genitor-like cells.





Non-Tg mice 105.0 ± 25.7 (n = 10) 206.1 ± 99.1 (n = 10)
Tg mice 77.4 ± 33.5 (n = 10)* 114.4 ± 63.6 (n = 10)*
Data are shown as mean ± SD. *p \ 0.05
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Fig. 4 HCaRG-Tg mice exhibit
lower tubular cell proliferation
after ischemia/reperfusion
injury (IRI). a Changes in the
kidney weight (KW)/body
weight (BW) ratio after IRI and
unilateral ureteral obstruction
(UUO). IRI increased KW
compared to nephrectomized
controls, and this increment was
significantly reduced
(*p \ 0.05) in Tg mice after
2 days. In the UUO model, KW
increased with hydronephrosis
caused by ureteral obstruction
for up to 3 days. After day 7,
KW started to decline, and
HCaRG elicited a significantly
more rapid reduction of KW
(p \ 0.05). b Localization of
proliferating cell nuclear
antigen (PCNA)-positive cells
on day 2 after IRI and on day 10
after UUO. The number of
PCNA-positive cells was
counted in tubular and
interstitial regions, respectively.
PCNA-positive cells in tubules
were lower in Tg than in non-Tg
mice. The black arrow indicates
PCNA-positive tubular cells,
and the white arrow depicts
PCNA-positive interstitial cells.
*p \ 0.05. Scale bars 50 lm.
Data from Matsuda et al. [21]
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Conclusion
Acute kidney injury occurs in various clinical settings,
including renal ischemia arising from septic shock and
major cardiovascular surgery, or acute drug or toxic expo-
sure. It is a common clinical problem with increasing
incidence and mortality, poor prognosis, and unsatisfactory
therapeutic options [51–54]. Despite better knowledge
acquired during the last decade of the pathophysiological
pathways underlying kidney diseases at both the basic
research and clinical levels, the progression of renal dys-
function and the number of hemodialyzed patients is still
increasing steadily every year. Repair after AKI involves
the proliferation of PTECs as well as migration and re-
differentiation. HCaRG has shown beneficial effects in
facilitating re-differentiation and controlling proliferation
through p21 induction via the p53-independent signaling
pathway during the renal repair phase (Fig. 5). HCaRG also
might stimulate the migration of PTECs during the repair
phase directly involving actin re-organization. Moreover,
IRI rapidly activates inflammatory responses, resulting in
endothelial dysfunction in the cortex [55]. HCaRG rap-
idly reduces inflammatory mediators and infiltration of
macrophages after reperfusion [21]. Sepsis-induced AKI
has a distinct pathophysiology which involves intrarenal
hemodynamic changes, vascular endothelial dysfunction,
infiltration of inflammatory cells in the renal parenchyma,
obstruction of tubules with apoptotic and necrotic cells, and
tubular epithelial mitochondrial dysfunction [56, 57].
HCaRG may have the potential to diminish these inflam-
matory responses and to prevent mitochondrial dysfunction
through maintenance of the tubular epithelial barrier not
only after IRI but also in sepsis-induced AKI. In addition,
lack of HCaRG might lead to uncontrolled cell proliferation
and migration, thus increasing the risk of oncogenesis of
RCC. In fact, HCaRG levels are significantly decreased in
tumors of brain, kidney and liver compared to normal
adjacent tissues [2] and rosiglitazone suppressed the growth
of gastric cancer by up-regulating HCaRG [58]. Tubular
regenerating functions mediated by HCaRG are most
important for improved renal function and survival after
AKI. Accelerated healing by HCaRG could serve as a new
therapeutic approach to AKI.
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